Long-term outcomes after treatment for relapsed or refractory Ph+ ALL
Retrospective Study of the Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
Group for Research in Adult Acute Lymphoblastic Leukemia · NCT07433400
This project looks back at adults with relapsed or refractory Philadelphia chromosome–positive (Ph+) ALL to see which treatment and response patterns link to better long-term outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Group for Research in Adult Acute Lymphoblastic Leukemia (other) |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT07433400 on ClinicalTrials.gov |
What this trial studies
This retrospective observational analysis reviews medical records of adults (≥18) with relapsed or refractory Ph+ ALL who were treated and monitored through the GRAALL network. Investigators will extract treatment details, use of tyrosine kinase inhibitors, response measures, and long-term progression and survival data. The team will analyze response profiles to identify patterns associated with longer remission or survival after relapse. No new treatments are given; the work uses existing clinical data to inform future therapeutic strategies.
Who should consider this trial
Good fit: Adults aged 18 or older with relapsed or refractory Ph+ ALL who were treated and followed at the participating GRAALL site(s).
Not a fit: Patients who are newly diagnosed, under 18, treated outside the GRAALL network, or who have incomplete medical records are unlikely to benefit from this retrospective analysis.
Why it matters
Potential benefit: If successful, the findings could help clinicians tailor treatments to improve long-term remission and survival for patients who relapse with Ph+ ALL.
How similar studies have performed: Previous observational and registry studies of Ph+ ALL, particularly those including TKIs, have shown improved outcomes, though detailed profiling of response after relapse remains relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 * Relapse or refractory Ph1 ALL Exclusion Criteria: * none
Where this trial is running
Pierre-Bénite
- GRAALL — Pierre-Bénite, France (RECRUITING)
Study contacts
- Study coordinator: Aline SCHMIDT, MD/PhD
- Email: alschmidt@chu-angers.fr
- Phone: 241354482
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ph Positive ALL, 1ST RELAPSE OR MORE, TKI